How US et EU biotech companies are evolving

Date: 20th Feb 2013

Venue: Hotel Principe di Savoia Piazza della Repubblica 17, 20124, Milano

Enjoy the true Milanese experience at Hotel Principe di Savoia, where effortless elegance meets timeless tradition. Dominating Milan�s Piazza della Repubblica, this spectacular landmark building has been the natural home for international travellers and cosmopolitan society since the 1920\'s.

US Biotech companies still lead the worldwide race for leadership, whatever metrics are used: number of companies, number of pipeline and in-market products, product sales, fund raising, corporate valuation, etc. EU companies in the meantime strive to gain momentum, often by accessing the US market and more recently, reaching out to Asia and Southern Hemisphere countries.

Join this event to:
- Explore price control and how complex health care access rules limit penetration in the EU
- Investigate how Obamacare reform in the US should benefit Industry at large and Biotech in particular.
- Discover how the narrowing of targeted indications for new products (for example bispecific antibodies) is changing for EU and US companies
- Focus on the ever increasing complexity of biotech drug development

Expert Talk by Claude Allery Senior Advisor, Bionest Partners. Claude has over 30 years of pharmaceuticals industry and management consulting experience in Europe and North America, and has held several corporate and operational finance and marketing positions.

Who should attend;

- Heads of R&D
- Therapeutic Area Heads
- Clinical Trial Managers

Event Location